Fig. 9

The profiles of immunotherapy sensitivity, immune infiltration and somatic mutation in HNSCC patients. A The correlation between the risk score and known biological processes and signaling pathways in tumor microenvironment. B The correlation between risk scores and tumor immune dysfunction and exclusion (TIDE) scores, myeloid-derived suppressor cell (MDSC), T cell exclusion scores, and T cell dysfunction scores. C The proportion of patients with different immunotherapy responses in risk groups from dataset GSE159067 and the difference of risk scores between immunotherapy response groups. D The expression levels of immune checkpoint genes in two risk groups. E The calculated proportion of 22 immune cells in two risk groups. F Heatmap showing the correlation significance between immune cells and model candidate genes. G The correlation between the risk score and tumor mutation burden (TMB) score. H The mutation landscape of HNSCC patients in two risk groups. The barplot represents the composition of mutation type and the percentage represents the mutation frequency of each gene. PD: progressive disease; SD: stable disease; PR: partial response; CR: complete response. * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001